From Financial Modeling Prep: 2025-05-06 09:14:00

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is a leading global musculoskeletal healthcare company specializing in orthopedic reconstructive products. Competitors include Stryker Corporation and Johnson & Johnson.

Analyst Rick Wise set a $115 price target for Zimmer Biomet on May 6, 2025, with the stock trading at $90.48, indicating a potential 27.1% upside. However, the stock dropped nearly 10% after disappointing first-quarter results.

Despite structural advantages, Zimmer Biomet faces challenges from high interest rates, trade tensions, and increased competition, leading to a current stock price of $90.48, down 11.62% with a -$11.9 change. Tariffs are expected to impact cash flows and share prices until resolved.

Zimmer Biomet’s market capitalization is around $17.9 billion, with a trading volume of 6,781,537 shares on the NYSE. In the past year, the stock has ranged from $89.92 to $122.25.



Read more at Financial Modeling Prep:: Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Faces Chal…